Document:

<PAGE>

                               IQ BIOMETRIX, INC.

                        2004 CONSULTANT COMPENSATION PLAN
                             AMENDED OCTOBER 8, 2004

1.       PURPOSE.

         The IQ Biometrix, Inc. 2004 Consultant Compensation Plan (the "Plan")
is intended to promote the interests of IQ Biometrix, Inc. and its subsidiaries
(collectively the "Corporation") by offering those outside consultants of the
Corporation who assist in the development and success of the business of the
Corporation, the opportunity to participate in a compensation plan designed to
reward them for their services and to encourage them to continue to provide
services to the Corporation.

2.       DEFINITIONS.

         For all purposes of this Plan, the following terms shall have the
following meanings:

         "Common Stock" means IQ Biometrix, Inc. common stock, $.01 par value.

         "Conditional Shares" means shares of Common Stock awarded under this
Plan subject to conditions imposed by the Committee (as defined herein) or the
conditions set forth in Section 6.2 or both.

         "IQ Biometrix" means IQ Biometrix, Inc., a Delaware corporation.

         "Subsidiary" means any company of which IQ Biometrix, Inc. owns,
directly or indirectly, the majority of the combined voting power of all classes
of stock.

         "Unconditional Shares" means shares of Common Stock awarded under this
Plan subject to no conditions.

3.       ADMINISTRATION.

         The Plan shall be administered by a committee (the "Committee") of not
less than two directors of IQ Biometrix selected by, and serving at the pleasure
of, IQ Biometrix's Board of Directors (the "IQ Biometrix Board").

         IQ Biometrix or any Subsidiary will recommend to the Committee persons
to whom shares may be awarded. The Committee shall make all final decisions with
respect to the persons to whom awards shall be granted ("Participants"), the
number of shares that shall be covered by each award or sale, the time or times
at which awards shall be granted or sales shall be made, the timing of when
awards shall vest, the terms and provisions of the instruments by which awards
or sales shall be evidenced, the interpretation of the Plan and all
determinations necessary or advisable for its administration. The Committee's
decisions, determinations and interpretations shall be final and binding on all
Participants.

<PAGE>

4.       ELIGIBILITY.

         Only individuals who are outside consultants, or directors, officers,
partners or employees of outside consultants, of IQ Biometrix or any Subsidiary
(a "Service Provider") shall be granted awards.

5. STOCK SUBJECT TO THE PLAN.

         The stock, which may be awarded or sold pursuant to this Plan, shall be
shares of Common Stock. When shares of Common Stock are awarded or sold, IQ
Biometrix may award or sell authorized but unissued Common Stock, or IQ
Biometrix may award or sell issued Common Stock held in its treasury. Each of
the respective boards of IQ Biometrix and all Subsidiaries involved in the award
or sale will fund the Plan to the extent so required to provide Common Stock for
the benefit of Participants. The total number of shares of Common Stock which
may be granted or sold under this Plan shall not exceed 2,000,000 shares in the
aggregate. Any shares awarded and later forfeited are again subject to award or
sale under the Plan.

6.       SHARE AWARDS AND SALES.

         6.1      GRANT OF SHARE AWARDS.

         The Committee may award to Participants Unconditional Shares and
Conditional Shares. The Committee will determine for each Participant selected
to be awarded Unconditional Shares and Conditional Shares the time or times when
Unconditional Shares or Conditional Shares shall be awarded and the number of
shares of Common Stock to be covered by each Unconditional Shares or Conditional
Share award. Unless expressly specified as Conditional Shares by the Committee,
all shares of Common Stock awarded under this Plan shall be Unconditional
Shares. No Unconditional Shares or Conditional Shares shall be awarded unless IQ
Biometrix (in the judgment of the Committee) has received from the Participant
either (a) a full performance of the services for which the Unconditional Shares
or Conditional Shares are being awarded, or (b) (i) a partial performance of the
services for which the Unconditional Shares or Conditional Shares are being
awarded and the value of such partial performance (in the judgment of the
Committee) equals or exceeds the aggregate par value of the Unconditional Shares
or Conditional Shares to be awarded and (ii) a binding obligation from the
Participant to provide in the future the remainder of the services for which the
Unconditional Shares or Conditional Shares are being awarded.

                                       2
<PAGE>

         6.2      CONDITIONS.

         Shares of Common Stock issued to a Participant as a Conditional Shares
award will be subject to the following conditions as well as all other
conditions imposed by the Committee ("Share Conditions"):

                  (a) Except as set forth in Paragraphs 6.4 and 6.5, if Share
         Conditions are not satisfied, Conditional Shares will be forfeited and
         returned to IQ Biometrix or, in the event such Conditional Shares were
         provided to the Participant from shares of Common Stock purchased by
         the Subsidiary, then the Conditional Shares will be returned to the
         Subsidiary. In either case, all rights of the Participant to such
         Conditional Shares will terminate without any payment of consideration
         by IQ Biometrix or the Subsidiary with which the Participant is
         associated, at such time as Participant ceases to be a Service Provider
         to IQ Biometrix or a Subsidiary.

                  (b) During the condition period ("Condition Period") relating
         to a Conditional Share award, none of the Conditional Shares subject to
         such award may be sold, assigned, bequeathed, transferred, pledged,
         hypothecated or otherwise disposed of in any way by the Participant.

                  (c) The Committee may require the Participant to enter into an
         escrow agreement providing that the certificates representing
         Conditional Shares sold or granted pursuant to the Plan will remain in
         the physical custody of IQ Biometrix or the applicable Subsidiary or an
         escrow holder during the Condition Period.

                  (d) Certificates representing Conditional Shares sold or
         granted pursuant to the Plan may bear a legend making an appropriate
         reference to the conditions imposed on the Conditional Shares.

                  (e) The Committee may impose other conditions on any
         Conditional Shares issued pursuant to the Plan as it may deem
         advisable, including without limitations, restrictions under the
         Securities Act of 1933, as amended, under the requirements of any stock
         exchange upon which such share or shares of the same class are then
         listed and under any state securities laws or other securities laws
         applicable to such shares.

         6.3      RIGHTS OF A STOCKHOLDER.

         Except as set forth in Paragraph 6.2(b), the recipient of a Conditional
Share award will have all of the rights of a stockholder of IQ Biometrix with
respect to the Conditional Shares, including the right to vote the Conditional
Shares and to receive all dividends or other distributions made with respect to
the Conditional Shares.

                                       3
<PAGE>

         6.4      LAPSE OF CONDITIONS.

         In the event of the termination of association of a Participant during
the Condition Period by reason of death, disability, or termination of
association, the Committee may, at its discretion, remove Share Conditions on
Conditional Shares.

         Conditional Shares to which the Share Conditions have not so lapsed
will be forfeited and returned to the Corporation as provided in Paragraph
6.2(a).

         6.5      LAPSE OF CONDITIONS AT DISCRETION OF THE COMMITTEE.

          The Committee may shorten the Condition Period or remove any or all
Share Conditions if, in the exercise of its absolute discretion, it determines
that such action is in the best interests of the Corporation and equitable to
the Participant.

         6.6      LISTING AND REGISTRATION OF SHARES.

         IQ Biometrix may, in its reasonable discretion, postpone the issuance
and/or delivery of any shares of Common Stock awarded or sold pursuant to this
Plan until completion of stock exchange listing, or registration, or other
qualification of such shares under any law, rule or regulation.

         6.7      DESIGNATION OF BENEFICIARY.

         A Participant may, with the consent of the Committee, designate a
person or persons to receive, in the event of death, any shares of Common Stock
to which such Participant would then be entitled pursuant to this Plan. Such
designation will be made upon forms supplied by and delivered to the Committee
and may be revoked in writing by the Participant. If a Participant fails
effectively to designate a beneficiary, then such Participant's estate will be
deemed to be the beneficiary.

7.       CAPITAL ADJUSTMENTS.

         The number and consideration of Common Stock covered by each award
granted or each sale under this Plan and the total number of shares that may be
granted or sold under the Plan shall be proportionally adjusted to reflect,
subject to any required action by stockholders, any stock dividend or split,
recapitalization, merger, consolidation, spin-off, reorganization, combination
or exchange of shares or other similar corporate change.

8.       APPROVALS.

         The issuance of shares pursuant to this Plan is expressly conditioned
upon obtaining all necessary approvals from all regulatory agencies from which
approval is required.

                                       4
<PAGE>

9.       INVESTMENT REPRESENTATIONS.

         As a condition to the Award, the Corporation may require the
Participant to represent and warrant at the time of any such exercise that the
Shares are being acquired only for investment and without any present intention
to sell or distribute such Shares if, in the opinion of counsel for the
Corporation, such a representation is required.

10.      EFFECTIVE DATE OF PLAN.

         The effective date of the Plan is February 13, 2004.

11.      TERM AND AMENDMENT OF PLAN.

         This Plan shall expire on December 31, 2004 (except to Conditional
Shares outstanding on that date). IQ Biometrix Board may terminate or amend the
Plan in any respect at any time, except no action of the IQ Biometrix Board, the
Committee or IQ Biometrix's stockholders, however, may, without the consent of a
Participant, alter or impair such Participant's rights under any Conditional
Shares previously granted.

         Neither the Plan nor any Award shall confer upon a Participant any
right with respect to continuing the Participant's relationship as a Service
Provider with the Corporation, nor shall they interfere in any way with the
Participant's right or the Corporation's right to terminate such relationship at
any time, with or without cause.

12.      NO RIGHT OF ASSOCIATION.

         Neither the action of IQ Biometrix in establishing this Plan, nor any
action taken by any IQ Biometrix Board or any Subsidiary or the Committee, nor
any provision of the Plan itself, shall be construed to limit in any way the
right of IQ Biometrix to terminate a Participant's association with the
Corporation at any time.

13.      WITHHOLDING TAXES.

         IQ Biometrix or any Subsidiary, as applicable, shall have the right to
deduct withholding taxes from any payments made pursuant to the Plan or to make
such other provisions as it deems necessary or appropriate to satisfy its
obligations to withhold federal, state or local income or other taxes incurred
by reason of payment or the issuance of Common Stock under the Plan. Whenever
under the Plan, Common Stock is to be delivered upon vesting of Conditional
Shares, the Committee shall be entitled to require as a condition of delivery
that the Participant remit or provide for the withholding of an amount
sufficient to satisfy all federal, state and other government withholding tax
requirements related thereto.

                                       5
<PAGE>

14.      PLAN NOT A TRUST.

         Nothing contained in the Plan and no action taken pursuant to the Plan
shall create or be construed to create a trust of any kind, or a fiduciary
relationship, between the Corporation and any Participant, the executor,
administrator or other personal representative, or designated beneficiary of
such Participant, or any other persons. If and to the extent that any
Participant or such Participant's executor, administrator or other personal
representative, as the case may be, acquires a right to receive any payment from
the Corporation pursuant to the Plan, such right shall be no greater than the
right of an unsecured general creditor of the Corporation.

15.      NOTICES.

         Each Participant shall be responsible for furnishing the Committee with
the current and proper address for the mailing of notices and delivery of Common
Stock pursuant to the Plan. Any notices required or permitted to be given shall
be deemed given if addressed to the person to be notified at such address given
to the Committee by such person and mailed by regular United States mail,
first-class and prepaid. If any item mailed to such address is returned as
undeliverable to the addressee, mailing will be suspended until the Participant
furnishes the proper address. This provision shall not be construed as requiring
the mailing of any notice or notification if such notice is not required under
the terms of the Plan or any applicable law.

16.      SEVERABILITY OF PROVISIONS.

         If any provisions of this Plan shall be held invalid or unenforceable,
such invalidity or unenforceability shall not affect any other provisions
hereof, and this Plan shall be construed and enforced as if such provisions had
not been included.

17.      PAYMENT TO MINORS, ETC.

         Any benefit payable to or for the benefit of a minor, an incompetent
person or other person incapable of receipting therefor shall be deemed paid
when paid to such person's guardian or the party providing or reasonably
appearing to provide for the care of such person, and such payment shall fully
discharge the Committee, the IQ Biometrix Board, the Corporation and other
parties with respect thereto.

18.      HEADINGS AND CAPTIONS.

         The headings and captions herein are provided for reference and
convenience only, shall not be considered part of the Plan, and shall not be
employed in the construction of the Plan.

                                       6
<PAGE>

19.      CONTROLLING LAW.

         This Plan shall be construed and enforced according to the laws of the
State of California to the extent not preempted by federal law, which shall
otherwise control.

20.      ENFORCEMENT OF RIGHTS.

         In the event the Corporation or a Participant is required to bring any
action to enforce the terms of this Plan, the prevailing party shall be
reimbursed by the non-prevailing party for all costs and fees, including actual
attorney fees, for bringing and pursuing such action.

                                       7ATHENA CAPITAL PARTNERS, INC. LETTER HEAD

CONFIDENTIAL

April 10, 2003

Mr. Richard Gabriel, CEO and
Hector Gomez, M.D., Ph.D., Chairman
DNAPrint Genomics 900 Cocoanut
Avenue Sarasota, FL 34236

Gentlemen:

         This letter agreement (the "Agreement") shall confirm the engagement of
Athena Capital Partners, Inc. ("Athena") by DNAPrint Genomics (the "Company") as
the Company's exclusive investment banking agent to:

1.       Arrange and negotiate a private placement of securities, issued by the
         Company and/or any of its subsidiaries or affiliates, in the form of
         common stock, convertible preferred stock, convertible debt, debt with
         warrants, or any other equity-linked securities (the "Securities"). The
         current plans are to raise $2.0 to $3.0 million at a pre-money
         valuation of $10.0 to $15.0 million.

2.       Obtain grant money from various governmental entities. The current plan
         is raise $500,000 to $1.0 million.

3.       Provide advisory services related to merger & acquisition activity, as
         requested by the Company.

The above-mentioned services are subject to the following terms and conditions:

         1. Exclusive Authorization. Subject to the terms and conditions of this
Agreement, the Company hereby appoints Athena to act on a best efforts basis as
its exclusive agent (except as it relates to the co-management relationship
discussed in paragraph 7 and the public sale of registered securities discussed
in paragraph 8) during the Authorization Period (as hereinafter defined) in all
the Company's investment banking activities, including the effort to privately
place the Securities (the "Transaction") in an amount and on terms and
conditions satisfactory to the Company. Athena hereby accepts such agency and
agrees on the terms of this Agreement to use its best efforts during

                                       -1-

<PAGE>

the Authorization Period to arrange the sale of the Securities through such a
private placement to potential investors (the "Investors"). The Company
understands that Athena shall not have any obligation hereunder to purchase any
of the Securities or to provide financing of any kind to the Company. In
addition, the Company agrees that it will not hold Athena liable or responsible
in the event that the Transaction is not consummated for any reason whatsoever,
including, but not limited to, an adverse change in the financial or security
markets, insufficient demand for instruments similar to the Securities, or a
lack of interest by Investors in the Transaction. During the Authorization
Period, the Company shall be prohibited from (i) directly or indirectly offering
any of the Securities (or instruments substantially similar to the Securities)
for sale to, or soliciting any offer to purchase any of the Securities (or
instruments substantially similar to the Securities) from, or otherwise
contacting, approaching or negotiating with respect thereto with, any person,
and (ii) authorizing anyone other than Athena to act on its behalf to place the
Securities (or instruments substantially similar to the Securities). The Company
shall promptly refer to Athena all offers, inquiries and proposals relating to
any placement of the Securities (or instruments substantially similar to the
Securities) made to the Company at any time during the Authorization Period.

         2. Authorization Period. Athena's engagement hereunder shall become
effective on the date this engagement letter is executed (the "Execution Date")
and, unless earlier terminated or extended in writing by the Company and/or
Athena, shall expire in twelve (12) months from the Execution Date (the
"Termination Date"; the period from the Execution Date through the Termination
Date being hereinafter referred to as the "Authorization Period").

         3. Offering Materials. In connection with its engagement hereunder, the
Company shall prepare a Confidential Offering Materials, and such amendments or
supplements thereto as the Company may reasonably deem to be necessary or
appropriate to effectuate the sale of the Securities (the Confidential Offering
Material, as the same may be amended or supplemented from time to time, is
referred to herein as the "Offering Materials") and Athena shall cooperate and
assist the Company in the preparation of the Offering Materials, which shall
include: a business plan, comparable analysis, valuation analysis, etc. Prior to
any distribution thereof, the Offering Materials shall be subject to Athena's
and the Company's review and approval.

         4. Fees and Disbursements.

         (a) As compensation for Athena's services hereunder, the Company shall
pay Athena fees and issue and deliver warrants to Athena as follows:

         (i)      upon the execution of this Agreement, a retainer, payable in
                  warrants of the Company (no cash), in such amount that
                  represents $80,000 of the value of the Company (determined by
                  a 20 day moving average). This Retainer shall be
                  non-refundable, except as described below. Upon a closing of a
                  Transaction, one-half of the value of the Retainer (i.e.
                  warrants representing $40,000 in value) shall be credited
                  against the warrant portion of the fees payable to Athena
                  pursuant to subparagraph 4(a)(iii) below;

         (ii)     upon the closing of a Transaction, a transaction fee (the
                  "Transaction Fee") payable in cash to Athena in an amount
                  equal to 6% of the Aggregate

                                       -2-

<PAGE>

                  Consideration (as defined below) paid for the Securities by
                  Investors; provided, however, that the Transaction Fee shall
                  be an amount not less than, in any circumstance, $165,000 (the
                  "Minimum Fee"). If the Aggregate Consideration is less than
                  $1.0 million then the Minimum Fee shall be 16.5% of the
                  Aggregate Consideration; and

         (iii)    upon the closing of a Transaction, the Company shall issue to
                  Athena warrants for a nominal price to purchase such number of
                  shares of the common stock of the Company equal to 4% of the
                  Aggregate Consideration (as defined below) paid for the
                  Securities by Investors, which warrants would be exercisable
                  for a period of five (5) years from the date of such closing,
                  at an exercise price per share equal to that paid by Investors
                  in the Transaction. The terms of the warrants shall be set
                  forth in a warrant agreement in form and substance
                  satisfactory to Athena and the Company, which shall contain
                  terms substantially identical to those applicable to the
                  Securities issued to Investors in the Transaction, including,
                  without limitation, anti-dilution provisions, registration
                  rights, and cashless exercise. The Company, at its option, may
                  elect to pay this portion of the fee in cash instead of
                  warrants.

         (iv)     upon the receipt of grant money (as discussed in item 2 of the
                  introductory paragraph of this engagement letter), the Company
                  shall issue to Athena warrants for a nominal price to purchase
                  such number of shares of the common stock of the Company equal
                  to $35,000 of the value of the Company, which warrants would
                  be exercisable for a period of five (5) years from the date of
                  such closing, at an exercise price per share equal to that
                  paid by Investors in the Transaction. The terms of the
                  warrants shall be set forth in a warrant agreement in form and
                  substance satisfactory to Athena and the Company, which shall
                  contain terms substantially identical to those applicable to
                  the Securities issued to Investors in the Transaction,
                  including, without limitation, anti-dilution provisions and
                  registration rights.

         (v)      fees for merger & acquisition advisory services will include a
                  monthly retainer plus a success fee equal to a percentage of
                  the "Transaction Value". For purposes of this Agreement the
                  Transaction Value shall mean the market value of the stock of
                  the target plus the book value of the target's debt (the
                  target's enterprise value). Athena and the Company will
                  negotiate in good faith to arrive at a reasonable fee.

         (vi)     Fees for the public sale of registered securities during the
                  Authorization Period, are discussed in paragraph 8 below.

         (b) In addition to the fees payable to Athena hereunder and regardless
of whether the sale of any of the Securities is consummated, the Company shall
reimburse Athena, upon request made from time to time, for all of Athena's
out-of-pocket expenses incurred in connection with this engagement, including
the fees, disbursements and other charges of Athena's legal

                                       -3-

<PAGE>

counsel. The Company acknowledges that Athena has a monthly administrative
charge (the administrative charge includes small dollar charges for items such
as long distance telephone calls, regular mail postage, photocopies, etc. It
does not include charges such as fedex charges or charges for operator assisted
conference calls) of $200, in addition to specific direct reimbursable charges.
All expenses greater than $500 per month will be pre-approved by Company.

         (c) The Company shall pay to Athena all fees and issue and deliver
warrants to Athena as described in Section 4 of this Agreement in the event that
at any time prior to the expiration of 12 months after the Termination Date any
of the Securities (or instruments substantially similar to the Securities) are
sold to any Investor identified and/or contacted during the Authorization
Period.

         (d) The Company shall pay to Athena all fees and issue and deliver
warrants to Athena as described in Section 4 of this Agreement in the event that
at any time prior to the expiration of 12 months after the Termination Date
substantially all of the assets of the Company are sold to any Investor
identified and/or contacted during the Authorization Period.

         (e) If a Transaction has been consummated and one or more Additional
Transactions (for purposes of this Agreement "Additional Transactions" shall
mean the sale of securities other than the Securities contemplated in this
engagement letter) are consummated by the Company (or any affiliate or
subsidiary thereof) within 12 months from the closing date of the initial
Transaction with any Investor identified and/or contacted during the
Authorization Period, Athena shall be entitled to receive (i) an additional fee
(the "Additional Fee") in an amount equal to 6% of the Aggregate Consideration
paid by the Investors in connection with any such Additional Transactions,
payable in cash upon the closing of any such Additional Transactions and (ii)
warrants equal to 4% of the Aggregate Consideration paid by the Investors in
such Additional Transactions, issuable and deliverable to Athena upon the
closing of any such Additional Transactions. Such warrants shall be exercisable
for a period of five years from the date of such closing, at an exercise price
per share equal to that paid by the Investors in the Additional Transactions.
The terms of the warrants shall be set forth in a warrant agreement in form and
substance satisfactory to Athena and the Company, which shall contain terms
substantially identical to those applicable to the Securities issued to
Investors in the Transaction, including, without limitation, anti-dilution
provisions, registration rights, and cashless exercise.

         (f) The definition of "Aggregate Consideration" for purposes of
calculating Athena's fee shall be deemed to include the cumulative fair market
value of all cash and other consideration paid for the Securities (or
instruments substantially similar to the Securities) by the Investors during the
Authorization Period, as well as any amounts paid in escrow and amounts payable
in the future. The fair market value of any non-cash consideration will be the
value determined by the Company and Athena at or prior to the date of the
applicable Transaction. The portion of Athena's fee relating to any future
payments shall be calculated and paid when and as such future payments are made;
provided, however, that the Minimum Fee payable to Athena pursuant to this
paragraph 4 shall be as described in paragraph 4 regardless of the timing of
future payments, if any.

                                       -4-

<PAGE>

         (g) All fees described above, and the reimbursement of Athena's
out-of-pocket expenses are payable by the Company as outlined above. The Company
will pay Athena, at a rate equal to twelve percent (12%) per year, a monthly
late payment charge (the "Late Payment Charge") on the unpaid balance of any
fees or expenses not timely paid in full. With respect to any unpaid portion of
the Transaction Fee or the Additional Fee, the Late Payment Charge will be
computed from the date of the closing of the Transaction or the Additional
Transaction, as applicable, until payment in full with respect to the unpaid
portion of any of Athena's out-of-pocket expenses, the Late Payment charge will
be computed from thirty (30) days after the issuance of Athena's invoice until
payment in full of such out-of-pocket expenses.

5.       Representations and Covenants. The Company represents and covenants as
         follows:

         (a) The Company shall make available to Athena and/or shall agree to
have professionally prepared at the Company's expense, all financial statements,
projections, appraisals, surveys, title abstracts, performance summaries and
other information which, by mutual agreement, shall be necessary or appropriate
for the proper marketing of the Securities and the completion of the financing
contemplated hereby.

         (b) During the Authorization Period, the Company shall not use,
distribute or refer to any Offering Materials (as hereinafter defined) without
mutual prior consent, except for internal use among the Company's personnel and
representatives and disclosure for the Securities and Exchange Commission.

         (c) All materials to be given to any potential investor in connection
with the offering or placement of the Securities shall be approved by both the
Company and Athena (all such materials, as so approved, together with the
Offering Materials, being referred to herein as the "Offering Material"). The
Company represents, warrants and agrees that the Offering Material as of the
date thereof was, and will be as of the closing date of each sale of Securities
(a "Closing Date"), true, complete and correct in all material respects and does
not, and will not, contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary in order to
make the statements contained therein not misleading. The Company shall advise
Athena immediately of the occurrence of any event or other change which results
in the Offering Material containing an untrue statement of a material fact or
omitting to state a material fact required to be stated therein or necessary to
make the statements contained therein not misleading. The Company recognizes and
confirms that Athena (i) will be using and relying primarily on the information
in the Offering Material and information available from generally recognized
public sources in performing the services contemplated hereunder without having
independently verified the same, (ii) does not assume responsibility for the
accuracy or completeness of such information or of the Offering Material and
(iii) will not make any appraisal of any assets of the Company. The Company will
cause to be furnished to Athena, at each closing of the sale of the Securities,
copies of "comfort" letters to be furnished to the purchasers of the Securities
on each Closing Date. Any letters provided to any party in connection with the
sale of the Securities and such letters as counsel to Athena may reasonably
request and the Company agrees are reasonable, dated the date of such closing,
in form and substance satisfactory to Athena.

                                       -5-

<PAGE>

         (d) The Company shall give Athena or will cause to be given Athena (i)
copies of the Company's annual reports and other financial reports at the
earliest time that such reports are made available to others, (ii) notice of any
material development affecting the Company, (iii) copies of all filings made by
the Company with the Securities and Exchange Commission, (iv) such other
information concerning the business and financial condition of the Company as
Athena may from time to time reasonably request and (v) access to the Company's
officers, directors, accountants, counsel and other advisors. Athena will obtain
approval from the Company's CEO and/or Chairman prior to contacting any of the
aforementioned advisors. In addition, the Company will, so long as any of the
Securities remain outstanding, furnish directly to Athena a copy of each
communication which is sent to the holders of the Securities as promptly as
practicable after the same is sent to them.

         (e) If any Securities are to be offered or sold outside of the United
States, prior to the distribution of any Offering Material, the Company shall
cause its counsel to (i) prepare and deliver to Athena an International
Securities Law Memorandum addressing securities laws and certain other issues
requested by Athena, and (ii) prepare and file all applicable filings or
registrations in the jurisdictions outside of the United States identified by
Athena, if any are required. The International Securities Law Memorandum shall
contain, among other things, the jurisdictions in which the Securities have been
qualified for offer and sale or in which Securities may be offered and sold
without prior governmental qualifications, as the case may be.

         (f) Upon each closing of a Transaction and an Additional Transaction,
the Company shall cause its counsel to prepare and file a Form D with the
Securities and Exchange Commission pursuant to Regulation D under the Securities
Act of 1933 together with all applicable state securities or "blue sky" filings
or registrations.

         (g) As a further inducement to Athena for accepting this engagement,
the Company agrees (assuming the successful completion of the private placement
discussed above) that for a period of 12 months after the termination of this
engagement, the Company shall notify Athena of any plans the Company may have to
consummate any (1) acquisition with respect to which the Company will engage a
financial advisor, (2) disposition for which the Company will engage a financial
advisor, (3) private placement of securities (other than the Transaction
governed by this Agreement), or (4) public offering of securities, and shall
grant to Athena the opportunity to act as exclusive financial advisor, lead
placement agent or managing underwriter in connection with any of the foregoing,
as the case may be, at fees and/or discounts which are mutually acceptable to
the Company and Athena; provided, however, that if Athena indicates that it is
willing to act as exclusive financial advisor, lead placement agent or managing
underwriter in connection with any of the foregoing, but Athena and the Company
are unable to agree upon an acceptable fee and/or discount, the Company may
engage any other appropriate financial institution to act as exclusive financial
advisor, lead placement agent or managing underwriter in connection therewith,
but only if (a) the fees payable to such other institution or the underwriting
discount which would be earned by such other institution, will be less than
those which Athena indicated it would accept, and (b) prior to engaging such
other financial institution, the Company offers Athena the opportunity to act as
exclusive financial advisor, lead placement agent or managing underwriter, as
the case may be, on the same financial terms that such other financial
institution had agreed to accept. The forgoing notwithstanding, under no
circumstances shall Athena be obligated to accept any offer to act as the

                                       -6-

<PAGE>

Company's advisor, placement agent or underwriter, and nothing contained herein
shall constitute the agreement of Athena to so act.

         (h) The Company agrees that during the Authorization Period, the
Company shall notify Athena of any plans the Company may have to consummate a
Sale Transaction (as defined below) in lieu of the Transaction, and shall grant
to Athena the opportunity to act as exclusive financial advisor in connection
with such Sale Transaction at the equivalent Transaction Fees provide herein as
used in this Agreement, the term "Sale Transaction" means, whether effected in
one transaction or a series of transactions: (a) any merger, consolidation,
reorganization or other business combination pursuant to which the business of
the Company is combined with that of another party or (b) the acquisition,
directly or indirectly, by any of the capital stock or assets of the Company by
way of a negotiated purchase or otherwise, or (c) any sale of substantially all
of the assets of the Company.

         (i) The Company represents, warrants and agrees that, except as
required by law or legal process, it will keep confidential, and will not
disclose to any third party, (i) the amount of the Transaction Fee, the
Additional Fee, and any other fees and expenses contemplated by this Agreement,
and (ii) the identities of the Investors identified or contacted by Athena.

6.       Indemnification.

         (a) Athena shall be indemnified and held harmless by the Company
against any losses, claims, damages or liabilities ("Claims") to which Athena
may become subject in connection with this Engagement. The Company will also
reimburse Athena for its expenses (including fees and expenses of legal counsel)
as such expenses are incurred in connection with investigating or defending such
Claims. However, the Company will not be obligated under this indemnity if it is
finally determined that such Claims arose out of the gross negligence or willful
misconduct of Athena. The reimbursement and indemnity obligations under this
paragraph shall be in addition to any liability the Company may otherwise have,
shall extend upon the same terms and conditions to the officers, directors,
members and employees of Athena, and shall be binding upon and inure to the
benefit of the parties and their respective successors and assigns.

         (b) The Company shall be indemnified and held harmless by Athena
against any Claims, other than fees and expenses discussed in Section 4 above,
to which the Company may become subject in connection with this Engagement.
Athena will also reimburse the Company for its expenses (including fees and
expenses of legal counsel) as such expenses are incurred in connection with
investigating or defending such Claims. However, Athena will not be obligated
under this indemnity if it is finally determined that such Claims arose out of
the gross negligence or willful misconduct of the Company. The reimbursement and
indemnity obligations under this paragraph shall be in addition to any liability
Athena may otherwise have, shall extend upon the same terms and conditions to
the officers, directors, members and employees of the Company, and shall be
binding upon and inure to the benefit of the parties and their respective
successors and assigns.

         (c) In the event Athena is requested or authorized by the Company or
required by government regulation, subpoena, or other legal process to produce
documents or personnel as

                                       -7-

<PAGE>

witnesses with respect to Athena's services for the Company, the Company will,
so long as it is not a party to the proceeding in which information is sought,
reimburse Athena for its professional time and expenses, as well as the fees and
expenses of Athena's counsel, incurred in responding to such requests.

         (d) Any controversy or claim arising out of or relating to this
Agreement or the services provided by Athena pursuant hereto (including any such
matter involving any parent subsidiary, affiliate, successor in interest, or
agent of the Company or of Athena) shall be submitted first to voluntary
mediation, and if mediation is not successful, then to binding arbitration in
accordance with the dispute resolution procedures set forth in Attachment 1.
Judgment on any arbitration award may be entered in any court having proper
jurisdiction.

         (e) In no event, regardless of the legal theory advanced, shall Athena
be liable or responsible to any person or entity including, but not limited to,
the Company other than for its gross negligence or willful misconduct and any
such liability shall be limited to the amount actually paid by the Company under
this Agreement. Neither party shall be liable to the other for consequential,
incidental, indirect, punitive or special damages (including loss of profits,
data, business or goodwill), regardless of the legal theory advanced or of any
notice given as to the likelihood of such damages, provided that this sentence
shall not apply to any such damages subject to indemnification under section 6.
The Company's recourse with respect to any liability or obligation of Athena
hereunder shall be limited to the assets of Athena, and the Company shall have
no recourse against, and shall bring no claim against, any director, officer or
employee of Athena or any of the assets thereof. Similarly, Athena's recourse
with respect to any liability or obligation of the Company hereunder shall be
limited to the assets of the Company, and Athena shall have no recourse against
and shall bring no claim against, any director, officer or employee of the
Company or any of the assets thereof.

         7. Co-Management. Athena has negotiated a co-management arrangement
with Sema4, Inc. with respect to the targets identified by Sema4, Inc. (targets
will be listed in an Exhibit A which shall be made a part this Agreement.
Exhibit A shall be completed after this agreement between Athena and the Company
has been executed and in connection with a separate letter of agreement between
Athena and Sema4, Inc. Sema4, Inc. has indicated they have three (3) targets
that will appear on Exhibit A). Such arrangement would call for a sharing of the
fee described in paragraph 4 between Athena and Semaphore. The current agreement
is that such fee will be shared 50/50 between Athena and Sema4, Inc.

         8. Public Sale of Registered Securities. The Company shall retain the
right to sell up to $1.2 million of registered shares to the public during the
Authorization Period. (The stated purpose of sales is to generate sufficient
cash to cover operating expenses prior to closing the private placement
discussed above.) Athena agrees that such sales will not violate the Exclusive
Authorization provisions described in paragraph 1 above. The Company agrees that
it will not unreasonably withhold its acceptance of funds raised in the private
placement in the amounts and for the fees described above. Furthermore, the
Company agrees to compensate Athena (for value received from Athena's services
that will benefit the public sales) at the rate of 2.083% of the amount raised
up to a maximum of $25,000. Such amount shall be in addition to the fees

                                       -8-

<PAGE>

discussed in paragraph 4 above and will be nonrefundable. Such fees shall be
creditable against termination fees discussed in paragraph 9 below.

         9. Miscellaneous. Athena's engagement hereunder may be terminated by
either the Company or Athena at any time upon written notice to that effect to
the other party, it being understood that the provisions hereof relating to the
payment of fees and expenses, the right to receive warrants and indemnification
and contribution and the right of first refusal with respect to certain future
transactions that may be undertaken by the Company will survive any termination,
expiration or supersession of this Agreement. Additionally, if the Company
terminates the Agreement prior to the end of the original Authorization Period,
the Company agrees to pay Athena the sum of $50,000 in recognition of the
services provide to date.

         THIS AGREEMENT WILL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH,
THE LAWS OF THE STATE OF FLORIDA APPLICABLE TO AGREEMENTS MADE AND TO BE
PERFORMED ENTIRELY IN SUCH STATE.

         EACH OF THE COMPANY AND ATHENA AGREE THAT ANY ACTION OR PROCEEDING
BASED HEREON, OR ARISING OUT OF ATHENA'S ENGAGEMENT HEREUNDER, SHALL BE BROUGHT
AND MAINTAINED EXCLUSIVELY IN THE COURTS OF THE STATE OF FLORIDA LOCATED IN THE
CITY AND COUNTY OF HILLSBOROUGH OR IN THE UNITED STATES DISTRICT COURT FOR THE
MIDDLE DISTRICT OF FLORIDA. THE COMPANY AND ATHENA EACH HEREBY IRREVOCABLY
SUBMIT TO THE JURISDICTION OF THE COURTS OF THE STATE OF FLORIDA LOCATED IN THE
CITY AND COUNTY OF HILLSBOROUGH OR IN THE UNITED STATES DISTRICT COURT FOR THE
MIDDLE DISTRICT OF FLORIDA FOR THE PURPOSE OF ANY SUCH ACTION OR PROCEEDING AS
SET FORTH ABOVE AND IRREVOCABLY AGREE TO BE BOUND BY ANY JUDGMENT RENDERED
THEREBY IN CONNECTION WITH SUCH ACTION OR PROCEEDING. EACH OF THE COMPANY AND
ATHENA HEREBY IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY
OBJECTION WHICH IT MAY HAVE OR HEREAFTER MAY HAVE TO THE LAYING OF VENUE OF ANY
SUCH ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY
CLAIM THAT ANY SUCH ACTION OR PROCEEDING HAS BEEN BROUGHT IN AN INCONVENIENT
FORUM.

         The Company (for itself, anyone claiming through it or in its name, and
on behalf of its equity holders) and Athena each hereby irrevocably waive any
right they may have to a trial by jury in respect of any claim based upon or
arising out of this Agreement or the transactions contemplated hereby. This
Agreement may not be assigned by either party without the prior written consent
of the other party.

         It is understood that Athena is being engaged hereunder solely to
provide the services described above to the Company and that Athena is not
acting as an agent or fiduciary of, and shall have no duties or liabilities to,
the equity holders of the Company or any third party in connection with its
engagement hereunder, all of which are hereby expressly waived.

                                       -9-

<PAGE>

         This Agreement (including the attached Indemnification Agreement)
embodies the entire agreement and understanding between the parties hereto and
supersedes all prior agreements and understandings relating to the subject
matter hereof. This Agreement may not be amended or otherwise modified or waived
except by an instrument in writing signed by both Athena and the Company. If any
provision of this Agreement is determined to be invalid or unenforceable in any
respect, such determination will not effect such provision in any other respect
or any other provision of this Agreement, which will remain in full force and
effect.

Please confirm that the foregoing correctly sets forth our agreement by signing
and returning to Athena the enclosed duplicate copy of this Agreement.

                                               Very truly yours,

                                               ATHENA CAPITAL PARTNERS, INC.

                                               By: /s/ Lisa R. Weiss
                                               ------------------------------
                                                   Lisa R. Weiss, CFA
                                                   President

THIS AGREEMENT CONTAINS A PRE-DISPUTE ARBITRATION CLAUSE LOCATED IN PARAGRAPH 6
ENTITLED "INDEMNIFICATION".

Accepted and Agreed to as of the date first written above:

DNAPRINT GENOMICS

Signature                                      Title
         ----------------                           --------------

Print Name                                     Date
         ----------------                           --------------

                                      -10-

<PAGE>

                                  ATTACHMENT 1

                          DISPUTE RESOLUTION PROCEDURES

The following procedures shall be used to resolve any controversy or claim
("dispute") as provided in our agreement dated March 31, 2003(the "Agreement").
If any of these provisions are determined to be invalid or unenforceable, the
remaining provisions shall remain in effect and binding on the parties to the
fullest extent permitted by law.

MEDIATION

A dispute shall be submitted to mediation by written notice to the other party
or parties. In the mediation process, the parties will try to resolve their
differences voluntarily with the aid of an impartial mediator, who will attempt
to facilitate negotiations. The mediator will be selected by agreement of the
parties. If the parties cannot otherwise agree on a mediator, one will be
appointed by the American Arbitration Association ("AAA"). However, any mediator
appointed by the AAA must be acceptable to all parties.

The mediation will be conducted as specified by the mediator and agreed upon by
the parties. The parties agree to discuss their differences in good faith and to
attempt, with the assistance of the mediator, to reach an amicable resolution of
the dispute.

The mediation will be treated as a settlement discussion and therefore will be
confidential. The mediator may not testify for either party in any later
proceeding relating to the dispute. No recording or transcript shall be made of
the mediation proceedings.

Each party will bear its own costs in the mediation. The fees and expenses of
the mediator will be shared equally by the parties.

ARBITRATION

If a dispute has not been resolved within 90 days after the written notice
beginning the mediation process (or a longer period, if the parties agree to
extend the mediation), the mediation shall terminate and the dispute will be
settled by arbitration. The arbitration will be conducted in accordance with the
procedures in this document and the Arbitration Rules for Professional
Accounting and Related Services Disputes of the AAA ("AAA" Rules). In the event
of a conflict, the provisions of this document will control.

The arbitration will be conducted before a panel of three arbitrators,
regardless of the size of the dispute, to be selected as provided in the AAA
Rules. Any issue concerning the extent to which any dispute is subject to
arbitration, or concerning the applicability, interpretation, or enforceability
of these procedures, including any contention that all or part of these
procedures are invalid or unenforceable, shall be governed by the Federal
Arbitration Act and resolved by the arbitrators. No potential arbitrator may
serve on the panel unless he or she has agreed in writing to abide and be bound
by these procedures.

                                      -11-

<PAGE>

Unless provided otherwise in the Agreement, the arbitrators may not award
non-monetary or equitable relief of any sort. They shall have no power to award
(i) damages inconsistent with the Agreement or (ii) punitive damages or any
other damages not measured by the prevailing party's actual damages, and the
parties expressly waive their right to obtain such damages in arbitration or in
any other forum. In no event, even if any other portion of these provisions is
held to be invalid or unenforceable, shall the arbitrators have power to make an
award or impose a remedy that could not be made or imposed by a federal court
deciding the matter in the same jurisdiction.

No discovery will be permitted in connection with the arbitration unless it is
expressly authorized by the arbitration panel upon a showing of substantial need
by the part seeking discovery.

All aspects of the arbitration shall be treated as confidential. Neither the
parties nor the arbitrators may disclose the existence, content or results of
the arbitration, except as necessary to comply with legal or regulatory
requirements. Before making any such disclosure, a party shall give written
notice to all other parties and shall afford such parties a reasonable
opportunity to protect their interests.

The results of the arbitration will be binding on the parties, and judgment on
the arbitrators' award may be entered in any court having jurisdiction.

                                      -12-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}]]